Dendritic cell-based vaccines

Clinical applications in breast cancer

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Recent evidence suggests that the immune system is involved in the carcinogenesis process and the antitumor immune responses impact the clinical outcome, thus emphasizing the concept of cancer immune surveillance. In this context, dendritic cells (DCs) seem to play a crucial role, as they are the most potent antigen-presenting cells (APCs) and are able to stimulate naive T lymphocytes and to generate memory T lymphocytes. Immunotherapy with DC-based vaccines is a very attractive approach to treat cancer, offering the potential for high tumor-specific cytotoxicity. Although breast cancer (BC) is traditionally considered a poorly immunogenic tumor, increasing numbers of both preclinical and clinical studies demonstrate that vaccination with DCs is capable of inducing an antitumor-specific response, while being well tolerated and safe. However, clinical objective responses are still disappointing and many reasons may explain the difficulty of developing effective DC-based therapies for BC. In this review, we discuss the characteristics of DCs, and the major clinical indications for DC-based immunotherapy in BC with related drawbacks.

Original languageEnglish
Pages (from-to)349-360
Number of pages12
JournalImmunotherapy
Volume6
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Dendritic Cells
Vaccines
Breast Neoplasms
Immunotherapy
Neoplasms
T-Lymphocytes
Antigen-Presenting Cells
Cell- and Tissue-Based Therapy
Immune System
Carcinogenesis
Vaccination

Keywords

  • breast cancer
  • dendritic cells
  • immune response
  • immunotherapies
  • vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology
  • Medicine(all)

Cite this

Dendritic cell-based vaccines : Clinical applications in breast cancer. / Gelao, Lucia; Criscitiello, Carmen; Esposito, Angela; Laurentiis, Michele De; Fumagalli, Luca; Locatelli, Marzia Adelia; Minchella, Ida; Santangelo, Michele; Placido, Sabino De; Goldhirsch, Aron; Curigliano, Giuseppe.

In: Immunotherapy, Vol. 6, No. 3, 2014, p. 349-360.

Research output: Contribution to journalArticle

@article{534ec99b1c684631987da1e2467cfc5e,
title = "Dendritic cell-based vaccines: Clinical applications in breast cancer",
abstract = "Recent evidence suggests that the immune system is involved in the carcinogenesis process and the antitumor immune responses impact the clinical outcome, thus emphasizing the concept of cancer immune surveillance. In this context, dendritic cells (DCs) seem to play a crucial role, as they are the most potent antigen-presenting cells (APCs) and are able to stimulate naive T lymphocytes and to generate memory T lymphocytes. Immunotherapy with DC-based vaccines is a very attractive approach to treat cancer, offering the potential for high tumor-specific cytotoxicity. Although breast cancer (BC) is traditionally considered a poorly immunogenic tumor, increasing numbers of both preclinical and clinical studies demonstrate that vaccination with DCs is capable of inducing an antitumor-specific response, while being well tolerated and safe. However, clinical objective responses are still disappointing and many reasons may explain the difficulty of developing effective DC-based therapies for BC. In this review, we discuss the characteristics of DCs, and the major clinical indications for DC-based immunotherapy in BC with related drawbacks.",
keywords = "breast cancer, dendritic cells, immune response, immunotherapies, vaccines",
author = "Lucia Gelao and Carmen Criscitiello and Angela Esposito and Laurentiis, {Michele De} and Luca Fumagalli and Locatelli, {Marzia Adelia} and Ida Minchella and Michele Santangelo and Placido, {Sabino De} and Aron Goldhirsch and Giuseppe Curigliano",
year = "2014",
doi = "10.2217/imt.13.169",
language = "English",
volume = "6",
pages = "349--360",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Dendritic cell-based vaccines

T2 - Clinical applications in breast cancer

AU - Gelao, Lucia

AU - Criscitiello, Carmen

AU - Esposito, Angela

AU - Laurentiis, Michele De

AU - Fumagalli, Luca

AU - Locatelli, Marzia Adelia

AU - Minchella, Ida

AU - Santangelo, Michele

AU - Placido, Sabino De

AU - Goldhirsch, Aron

AU - Curigliano, Giuseppe

PY - 2014

Y1 - 2014

N2 - Recent evidence suggests that the immune system is involved in the carcinogenesis process and the antitumor immune responses impact the clinical outcome, thus emphasizing the concept of cancer immune surveillance. In this context, dendritic cells (DCs) seem to play a crucial role, as they are the most potent antigen-presenting cells (APCs) and are able to stimulate naive T lymphocytes and to generate memory T lymphocytes. Immunotherapy with DC-based vaccines is a very attractive approach to treat cancer, offering the potential for high tumor-specific cytotoxicity. Although breast cancer (BC) is traditionally considered a poorly immunogenic tumor, increasing numbers of both preclinical and clinical studies demonstrate that vaccination with DCs is capable of inducing an antitumor-specific response, while being well tolerated and safe. However, clinical objective responses are still disappointing and many reasons may explain the difficulty of developing effective DC-based therapies for BC. In this review, we discuss the characteristics of DCs, and the major clinical indications for DC-based immunotherapy in BC with related drawbacks.

AB - Recent evidence suggests that the immune system is involved in the carcinogenesis process and the antitumor immune responses impact the clinical outcome, thus emphasizing the concept of cancer immune surveillance. In this context, dendritic cells (DCs) seem to play a crucial role, as they are the most potent antigen-presenting cells (APCs) and are able to stimulate naive T lymphocytes and to generate memory T lymphocytes. Immunotherapy with DC-based vaccines is a very attractive approach to treat cancer, offering the potential for high tumor-specific cytotoxicity. Although breast cancer (BC) is traditionally considered a poorly immunogenic tumor, increasing numbers of both preclinical and clinical studies demonstrate that vaccination with DCs is capable of inducing an antitumor-specific response, while being well tolerated and safe. However, clinical objective responses are still disappointing and many reasons may explain the difficulty of developing effective DC-based therapies for BC. In this review, we discuss the characteristics of DCs, and the major clinical indications for DC-based immunotherapy in BC with related drawbacks.

KW - breast cancer

KW - dendritic cells

KW - immune response

KW - immunotherapies

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=84899520319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899520319&partnerID=8YFLogxK

U2 - 10.2217/imt.13.169

DO - 10.2217/imt.13.169

M3 - Article

VL - 6

SP - 349

EP - 360

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 3

ER -